Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cryoport, Inc.CYRX · Entity 5125 | Chief Scientific Officer | March 23, 2026 | March 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cryoport, Inc.
Report date March 23, 2026 · Filed March 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 102,356 |
Reported balance
After 2026-03-23 transaction · row 1
1 source rowRow 1 · 2026-03-23 · Sale · Disposed 1,341 · Balance 102,356 F1: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 23, 2026 Filed Mar 26, 2026 00:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 1,341 | $8.18 | $10,969.38 |
DisclosureSEC source: 0001104659-26-034752 · tm269766-1_4seq1.xml · nonDerivative · entry 1 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,356 F1 · kind: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 00:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 3,235 | $8.00 | $25,880.00 |
DisclosureSEC source: 0001104659-26-029718 · tm269014-2_4seq1.xml · nonDerivative · entry 2 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,697 F2 · kind: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. Read SEC document |
| March 14, 2026 Filed Mar 18, 2026 00:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantStock Option (right to buy) · Derivative | 68,534 | $0.00 Strike: $8.60 | $0.00 |
DisclosureSEC source: 0001104659-26-029718 · tm269014-2_4seq1.xml · derivative · entry 3 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,534 Underlying: Common Stock · 68,534 shares Expires 2033-03-14 F3 · derivative.exercise_date: 1/48 of options vest on the 14th of each month for forty-eight months beginning April 14, 2026. Read SEC document |
| March 14, 2026 Filed Mar 18, 2026 00:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 22,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-029718 · tm269014-2_4seq1.xml · nonDerivative · entry 1 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,932 F1 · security: Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 14, 2027. F1 · price: Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 14, 2027. Read SEC document |
| March 24, 2025 Filed Mar 26, 2025 23:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 1,349 | $6.94 | $9,364.22 |
DisclosureSEC source: 0001104659-25-028324 · tm2510559-3_4seq1.xml · nonDerivative · entry 1 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,087 F1 · kind: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 23:06 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 2,092 | $6.29 | $13,162.24 |
DisclosureSEC source: 0001104659-25-025193 · tm259699-2_4seq1.xml · nonDerivative · entry 2 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,436 F2 · kind: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 23:06 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $7.05 | $0.00 |
DisclosureSEC source: 0001104659-25-025193 · tm259699-2_4seq1.xml · derivative · entry 3 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2032-03-14 F3 · derivative.exercise_date: 1/48 of options vest on the 14th of each month for forty-eight months beginning April 14, 2025. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 23:06 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-025193 · tm259699-2_4seq1.xml · nonDerivative · entry 1 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,528 F1 · security: Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 14, 2026. F1 · price: Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 14, 2026. Read SEC document |
| March 10, 2025 Filed Mar 11, 2025 23:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 1,583 | $4.88 | $7,723.62 |
DisclosureSEC source: 0001104659-25-022644 · tm258882-3_4seq1.xml · nonDerivative · entry 2 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,528 F2 · kind: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. Read SEC document |
| March 09, 2025 Filed Mar 11, 2025 23:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionRestricted Stock Rights · Derivative | 2,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-022644 · tm258882-3_4seq1.xml · derivative · entry 3 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The originally granted restricted stock rights vest in four equal annual installments beginning March 9, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2025. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F3 · derivative.exercise_date: The originally granted restricted stock rights vest in four equal annual installments beginning March 9, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2025. F3 · derivative.expiration_date: The originally granted restricted stock rights vest in four equal annual installments beginning March 9, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2025. Read SEC document |
| March 09, 2025 Filed Mar 11, 2025 23:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 2,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-022644 · tm258882-3_4seq1.xml · nonDerivative · entry 1 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F1 · price: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 00:08 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 1,367 | $17.54 | $23,980.32 |
DisclosureSEC source: 0001104659-24-039193 · tm249900-1_4seq1.xml · nonDerivative · entry 1 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,444 F1 · kind: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:50 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantStock Option (right to buy) · Derivative | 11,500 | $0.00 Strike: $16.70 | $0.00 |
DisclosureSEC source: 0001104659-24-036284 · tm249281-4_4seq1.xml · derivative · entry 6 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2031-03-15 F5 · derivative.exercise_date: 1/48 of options vest on the 15th of each month for forty-eight months beginning April 25, 2024. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:50 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-036284 · tm249281-4_4seq1.xml · nonDerivative · entry 4 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,811 F3 · security: Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 15, 2025. F3 · price: Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning March 15, 2025. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 23:50 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 1,312 | $15.43 | $20,247.05 |
DisclosureSEC source: 0001104659-24-036284 · tm249281-4_4seq1.xml · nonDerivative · entry 3 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,061 F2 · kind: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. Read SEC document |
| March 11, 2024 Filed Mar 19, 2024 23:50 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 1,418 | $16.35 | $23,187.70 |
DisclosureSEC source: 0001104659-24-036284 · tm249281-4_4seq1.xml · nonDerivative · entry 2 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,373 F2 · kind: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. Read SEC document |
| March 09, 2024 Filed Mar 19, 2024 23:50 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionRestricted Stock Rights · Derivative | 2,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-036284 · tm249281-4_4seq1.xml · derivative · entry 5 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,667 Underlying: Common Stock · 2,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The originally granted restricted stock rights vest in four equal annual installments beginning March 9, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2024. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F4 · derivative.exercise_date: The originally granted restricted stock rights vest in four equal annual installments beginning March 9, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2024. F4 · derivative.expiration_date: The originally granted restricted stock rights vest in four equal annual installments beginning March 9, 2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2024. Read SEC document |
| March 09, 2024 Filed Mar 19, 2024 23:50 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 2,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-036284 · tm249281-4_4seq1.xml · nonDerivative · entry 1 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,791 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F1 · price: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. Read SEC document |
| September 12, 2023 Filed Sep 13, 2023 21:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionStock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $12.79 | $0.00 |
DisclosureSEC source: 0001104659-23-100488 · tm2326093-1_4seq1.xml · derivative · entry 2 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,000 Underlying: Common Stock · 1,000 shares Expires 2029-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vested as part of an option that began vesting on the 1st of each month for forty-eight months beginning May 1, 2019. Read SEC document |
| September 12, 2023 Filed Sep 13, 2023 21:01 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 1,000 | $12.79 | $12,790.00 |
DisclosureSEC source: 0001104659-23-100488 · tm2326093-1_4seq1.xml · nonDerivative · entry 1 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,125 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: No Common Stock was sold by the reporting person in connection with the transactions disclosed on this Form 4. Read SEC document |
| March 22, 2023 Filed Mar 24, 2023 22:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantStock Option (right to buy) · Derivative | 20,910 | $0.00 Strike: $23.78 | $0.00 |
DisclosureSEC source: 0001104659-23-036712 · tm2310574-1_4seq1.xml · derivative · entry 2 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,910 Underlying: Common Stock · 20,910 shares Expires 2030-03-22 F2 · derivative.exercise_date: 1/48 of options vest on the 22nd of each month for forty-eight months beginning 4/22/2023. Read SEC document |
| March 22, 2023 Filed Mar 24, 2023 22:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 10,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-036712 · tm2310574-1_4seq1.xml · nonDerivative · entry 1 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,125 F1 · security: Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning 3/22/2024. F1 · price: Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning 3/22/2024. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:15 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 1,362 | $20.79 | $28,315.98 |
DisclosureSEC source: 0001104659-23-033873 · tm239899-3_4seq1.xml · nonDerivative · entry 1 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,670 F1 · kind: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 01:24 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 1,476 | $20.14 | $29,726.64 |
DisclosureSEC source: 0001104659-23-031940 · tm239488d2_4.xml · nonDerivative · entry 2 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,032 F2 · kind: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. Read SEC document |
| March 09, 2023 Filed Mar 14, 2023 01:24 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionRestricted Stock Rights · Derivative | 2,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-031940 · tm239488d2_4.xml · derivative · entry 3 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,333 Underlying: Common Stock · 2,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The originally granted restricted stock rights vest in four equal annual installments beginning 3/9/2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2023. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F3 · derivative.exercise_date: The originally granted restricted stock rights vest in four equal annual installments beginning 3/9/2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2023. F3 · derivative.expiration_date: The originally granted restricted stock rights vest in four equal annual installments beginning 3/9/2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2023. Read SEC document |
| March 09, 2023 Filed Mar 14, 2023 01:24 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 2,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-031940 · tm239488d2_4.xml · nonDerivative · entry 1 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,508 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F1 · price: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 23:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantStock Option (right to buy) · Derivative | 20,910 | $0.00 Strike: $29.69 | $0.00 |
DisclosureSEC source: 0001104659-22-034629 · tm229493-4_4seq1.xml · derivative · entry 2 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,910 Underlying: Common Stock · 20,910 shares Expires 2029-03-14 F2 · derivative.exercise_date: 1/48 of options vest on the 14th of each month for forty-eight months beginning 4/14/2022. Read SEC document |
| March 14, 2022 Filed Mar 16, 2022 23:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 10,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-034629 · tm229493-4_4seq1.xml · nonDerivative · entry 1 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,841 F1 · security: Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning 3/14/2023. F1 · price: Represents restricted stock rights, which are a contingent right to receive one share of CYRX common stock, that vest in four equal annual installments beginning 3/14/2023. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 22:45 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionRestricted Stock Rights · Derivative | 2,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-032997 · tm228984-1_4seq1.xml · derivative · entry 3 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 2,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The originally granted restricted stock rights vest in four equal annual installments beginning 3/9/2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2022. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F3 · derivative.exercise_date: The originally granted restricted stock rights vest in four equal annual installments beginning 3/9/2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2022. F3 · derivative.expiration_date: The originally granted restricted stock rights vest in four equal annual installments beginning 3/9/2022, and have no expiration date. The restricted stock rights reported herein vested and converted to shares of CYRX common stock on a one-for-one basis on March 9, 2022. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 22:45 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 1,410 | $31.05 | $43,780.50 |
DisclosureSEC source: 0001104659-22-032997 · tm228984-1_4seq1.xml · nonDerivative · entry 2 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,386 F2 · kind: Shares required to be sold in accordance with the Issuer's policies, in payment of taxes due upon the vesting of restricted stock rights. Read SEC document |
| March 09, 2022 Filed Mar 11, 2022 22:45 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 2,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-032997 · tm228984-1_4seq1.xml · nonDerivative · entry 1 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F1 · price: Represents the conversion of restricted stock rights to shares of common stock upon vesting. Each restricted stock right represents a contingent right to receive one share of CYRX common stock. Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 20:46 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOption to purchase common stock · Derivative | 16,577 | $0.00 Strike: $8.65 | $0.00 |
DisclosureSEC source: 0001104659-21-105168 · tm2125120d1_4.xml · derivative · entry 7 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,423 Underlying: Common Stock · 16,577 shares Expires 2028-03-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/48 of the 68,000 options originally granted vested on the 28th of each month for forty-eight months beginning April 28, 2018. Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 20:46 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOption to purchase common stock · Derivative | 77,625 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001104659-21-105168 · tm2125120d1_4.xml · derivative · entry 6 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 77,625 shares Expires 2025-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/48 of the 77,625 options originally granted vested on the 7th of each month for forty-eight months beginning June 7, 2015. Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 20:46 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 2,521 | $59.83 | $150,841.01 |
DisclosureSEC source: 0001104659-21-105168 · tm2125120d1_4.xml · nonDerivative · entry 5 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,129 F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.81 to $59.90, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 20:46 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 3,172 | $59.11 | $187,512.46 |
DisclosureSEC source: 0001104659-21-105168 · tm2125120d1_4.xml · nonDerivative · entry 4 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,650 F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.85 to $59.51, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 20:46 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 74,453 | $58.37 | $4,346,119.42 |
DisclosureSEC source: 0001104659-21-105168 · tm2125120d1_4.xml · nonDerivative · entry 3 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,822 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.85 to $58.84, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 20:46 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 16,577 | $8.65 | $143,391.05 |
DisclosureSEC source: 0001104659-21-105168 · tm2125120d1_4.xml · nonDerivative · entry 2 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2021 Filed Aug 13, 2021 20:46 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 77,625 | $7.80 | $605,475.00 |
DisclosureSEC source: 0001104659-21-105168 · tm2125120d1_4.xml · nonDerivative · entry 1 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 02:09 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOptions to purchase common stock · Derivative | 7,231 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001104659-21-035159 · tm219529d2_4seq1.xml · derivative · entry 10 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,231 shares Expires 2026-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/48th of the 70,000 options originally granted vested on the 6th of each month for forty-eight months beginning June 6, 2016. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 02:09 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOptions to purchase common stock · Derivative | 11,831 | $0.00 Strike: $3.21 | $0.00 |
DisclosureSEC source: 0001104659-21-035159 · tm219529d2_4seq1.xml · derivative · entry 9 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,831 shares Expires 2021-05-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 1/48th of the 78,000 options originally granted vested on the 18th of each month for forty-eight months beginning June 18, 2017. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 02:09 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOptions to purchase common stock · Derivative | 11,342 | $0.00 Strike: $3.07 | $0.00 |
DisclosureSEC source: 0001104659-21-035159 · tm219529d2_4seq1.xml · derivative · entry 8 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,342 shares Expires 2025-08-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/48th of the 77,625 options originally granted vested on the 7th of each month for forty-eight months beginning June 7, 2015. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 02:09 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 9,357 | $55.33 | $517,767.72 |
DisclosureSEC source: 0001104659-21-035159 · tm219529d2_4seq1.xml · nonDerivative · entry 5 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,073 Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 02:09 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 3,974 | $54.65 | $217,166.38 |
DisclosureSEC source: 0001104659-21-035159 · tm219529d2_4seq1.xml · nonDerivative · entry 4 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,430 Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 02:09 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 11,831 | $3.21 | $37,977.51 |
DisclosureSEC source: 0001104659-21-035159 · tm219529d2_4seq1.xml · nonDerivative · entry 3 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,404 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 02:09 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 7,231 | $1.87 | $13,521.97 |
DisclosureSEC source: 0001104659-21-035159 · tm219529d2_4seq1.xml · nonDerivative · entry 2 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 02:09 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 11,342 | $3.07 | $34,819.94 |
DisclosureSEC source: 0001104659-21-035159 · tm219529d2_4seq1.xml · nonDerivative · entry 1 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,342 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 09, 2021 Filed Mar 12, 2021 02:09 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantRestricted Stock Rights · Derivative | 10,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-035159 · tm219529d2_4seq1.xml · derivative · entry 7 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,667 Underlying: Common Stock · 10,667 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock right represents a contingent right to receive one share of CYRX common stock. F3 · derivative.exercise_date: The restricted stock rights vest in four equal annual installments beginning 3/9/2022. F3 · derivative.expiration_date: The restricted stock rights vest in four equal annual installments beginning 3/9/2022. Read SEC document |
| March 09, 2021 Filed Mar 12, 2021 02:09 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption to purchase common stock · Derivative | 21,333 | $0.00 Strike: $58.94 | $0.00 |
DisclosureSEC source: 0001104659-21-035159 · tm219529d2_4seq1.xml · derivative · entry 6 Sawicki Mark W · CIK 0001848218 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,333 Underlying: Common Stock · 21,333 shares Expires 2028-03-09 F1 · derivative.exercise_date: 1/48 of options vest on the 9th of each month for forty-eight months beginning 4/09/2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.